Amnestic mild cognitive impairment and conversion to alzheimer's disease: Insulin resistance and glycoxidation as early biomarker clusters

Journal of Alzheimer's Disease

Volumn 45, Issue 1, 2015, Pages 89-95

  Monacelli, Fiammetta ^a   Borghi, Roberta ^a   Cammarata, Sergio ^b   Nencioni, Alessio ^a   Piccini, Alessandra ^a   Tabaton, Massimo ^a   Odetti, Patrizio ^a,c  

^a UNIVERSITY OF GENOA   (Italy)

^b GALLIERA HOSPITAL   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Alzheimer's disease; early biomarkers; insulin resistance; malondialdehyde; mild cognitive impairment; pentosidine

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; GLUCOSE; INSULIN; MALONALDEHYDE; PENTOSIDINE; ARGININE; GLUCOSE BLOOD LEVEL; LYSINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCOXIDATION; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; QUANTITATIVE INSULIN SENSITIVITY CHECK INDEX; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; STATISTICS;

AGED; ALZHEIMER DISEASE; ARGININE; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; LYSINE; MALE; MALONDIALDEHYDE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; STATISTICS AS TOPIC;

EID: 84924157462     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142511     Document Type: Article

References (35)

1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
2. Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L (2014) Mild cognitive impairment: A concept in evolution. J Intern Med 275, 214-228.
3. Sabbagh MN, Cooper K, Stoehr JD, DeLange J, Thind K, Lahti T, Reisberg B, Sue L, Vedders L, Fleming SR, Beach TG (2010) Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD. Curr Alzheimer Res 7, 280-286.
4. Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF, Jicha GA, Ivnik RJ, Smith GE, Tangalos EG, Braak H, Kokmen E (2006) Neuropathological features of amnestic mild cognitive impairment. Arch Neurol 63, 665-667.
5. Assini A, Cammarata S, Vitali A, Colucci M, Giliberto L, Borghi R, Inglese ML, Volpe S, Ratto S, Dagna-Bricarelli F, Baldo C, Argusti A, Odetti P, Piccini A, Tabaton M (2004) Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology 63, 828-883.
6. Cammarata S, Borghi R, Giliberto L, Pardini M, Pollero V, Novello C, Fornaro M, Vitali A, Bracco L, Caltagirone C, Bossu P, Odetti P, TabatonM (2009) Amyloid-beta42 plasma levels are elevated in amnestic mild cognitive impairment. J Alzheimers Dis 18, 267-271.
7. Morales I, Guzman-Martinez L, Cerda-Troncoso C, Farias GA, Maccioni RB (2014) Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel. Front Cell Neurosci 22, 8-112.
8. Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X (2014) Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochim Biophys Acta 1842, 1240-1247.
9. Ko S, Lin Y, Lin Y, Chang S (2010) Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species. Free Radic Biol Med 49, 474-480.
10. ZhaoW, TownsendM (2009) Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 1792, 482-496.
11. Desai G, Zheng C, GeethaT, MathewsST, White BD, Huggins KW, Zizza CA, Broderick TL, Babu JR (2014) The pancreasbrain axis: Insight into disrupted mechanisms associating type 2 diabetes and Alzheimer's disease. J Alzheimers Dis 42, 347-356.
12. Kuljis RO, Salvkovic-Petrisic M (2011) Dementia, diabetes, Alzheimer's disease, and insulin resistance in the brain: Progress, dilemmas, new opportunities, and a hypothesis to tackle intersecting epidemics. J Alzheimers Dis 25, 29-41.
13. Kroner Z (2009) The relationship between Alzheimer's disease and diabetes. Type 3 diabetes? Altern Med Rev 14, 4.
14. Moreira PI (2012) Alzheimer's disease and diabetes: An integrative view of the role of mitochondria, oxidative stress, and insulin. J Alzheimers Dis 30 (Suppl 2), S199-S215.
15. Correia Sc, Santos RX, Carvalho C, Cardoso S, Candeias E, Santos MS, Oliveira CR, Moreira PI (2012) Insulin signaling, glucose metabolism and mitochondria: Major players in Alzheimer's disease and diabetes interrelation. Brain Res 1441, 64-78.
16. Takeda S, Sato N, Rakugi H, Morishita R (2011) Molecular mechanisms linking diabetes mellitus and Alzheimer disease: Beta-amyloid peptide, insulin signaling, and neuronal functioning. Mol Biosyst 7, 1822-1827.
17. Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, Mathis CA, Shiga T, Wester HJ, Kurz A, Drzezga A (2009) Beta amyloid in Alzheimer's disease: Increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65, 927-934.
18. Jack C JR, Knopman D, Jagust WC (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services task Forceon Alzheimer. Neurology 34, 939-944.
20. Odetti P, Fogarty J, Sell DR, Monnier VM (1992) Chromatographic quantification of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 4, 153-159.
21. Young S, Trimble ER (1991) Measurement of malondialdehyde in plasma by high performance liquid chromatography with fluorimetric detection. Ann Clin Biochem 28, 504-508.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, TurnerRC (1985) Homeostasis model assessment: Insulin resistance and beta cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28, 412-419.
23. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ (2000) Quantitative insulin sensitivity check index: A simple, accurate method for assessment insulin sensitivity in humans. J Clin Endocrinol Metab 85, 2402-2410.
24. Pratico D (2008) Oxidative stress hypothesis in Alzheimer's disease: A reappraisal. Trends Pharmacol Sci 29, 609-615.
25. Vicente Miranda HF, Outeiro TF (2010) The sour side of neurodegenerative disorders: The effects of protein glycation. J Pathol 221, 13-25.
26. Rahmadi A, Steiner N, Münch G (2011) Advanced glycation endproducts as gerontotoxin and biomarkers for carbonylbased degenerative processes in Alzheimer's disease. Clin Chem Lab Med 49, 385-391.
27. Guglielmotto M, Aragno M, Tamagno E, Vercellinatto I, Visentin S, Medana C, Catalano MG, Smith MA, Perry G, Danni O, Boccuzzi G, Tabaton M (2012) AGEs/RAGE complex upregulates BACE1 via NF-&brta;B pathway activation. Neurobiol Aging 33, 196. e13-27.
28. Lee S, Tong M, Hang S, Deochand C, De La Monte S (2013) CSF and brain indices of insulin resistance, oxidative stress and neuro-inflammation in early versus late Alzheimer's Fisease. J Alzheimers Dis Parkinsonism 3, 128.
29. Shinall H, Song ES, Hersh LB (2005) Susceptibility of amyloid beta peptide degrading enzymes to oxidative damage: A potential Alzheimer's disease spiral. Biochem 44, 15345-15350.
30. Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, Frautschy SA, ColeGM (2004) Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: Implications for Alzheimer's disease intervention. J Neurosci 24, 11120-11126.
31. Cole AR, Astell A, Green C, Sutherland C (2007) Molecular connexions between dementia and diabetes. Neurosci Biobehav Rev 31, 1046-1063.
32. Salminen A, Ojala J, Suuronen T, Karniranta K, Kauppinen A (2008) Amyloid-beta oligomers set fire to inflammosomes and induce Alzheimer's pathology. J Cell Mol Med 12, 2255-2262.
33. Batterfield DA, Reed T, Shelley FN, Sultana R (2007) Roles of amyloid beta-peptide associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 43, 658-677.
34. Rijpma A, Meulenbroek O, Olde Rikkert MG (2014) Cholinesterase inhibitors and add-on nutritional supplements in Alzheimer's disease: A systematic review of randomized controlled trials. Ageing Res Rev 16C, 105-112.
35. Lannfelt L, Relkin NR, Siemers ER (2014) Amyloid-β-directed immunotherapy for Alzheimer's disease. J Intern Med 275, 284-295.